Guess what day it is
Before we get started with an analysis of the results released by Novo Nordisk it’s appropriate that slide deck used by the company ran 138 slides. Keep in mind this is not full year results but quarterly results – this is so damn Novo.
Just as Lilly is focused on GLP-1 sales Novo too is now GLP-1 first insulin second. Just look at this from their earnings announcement
“Sales of GLP-1 diabetes products in North America Operations increased by 13% measured in Danish kroner and by 24% at CER. Novo Nordisk is the market leader with a . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.